Back to top
more

Baxter International (BAX)

(Delayed Data from NYSE)

$35.25 USD

35.25
3,583,367

+0.08 (0.23%)

Updated May 17, 2024 04:00 PM ET

After-Market: $35.28 +0.03 (0.09%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (145 out of 249)

Industry: Medical - Products

Better trading starts here.

Zacks News

Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.

Amedisys (AMED) Beats on Q1 Earnings, Revenues Meet Mark

Amedisys Inc. (AMED) reported adjusted earnings from continuing operations of 47 cents per share in the first quarter of 2017, up 42.4% year over year.

    Luminex (LMNX) Tops Q1 Earnings, Revenue Guidance Raised

    Luminex Corporation (LMNX) reported earnings of 27 cents per share in the first quarter of 2017, surpassing the Zacks Consensus Estimate of adjusted earnings of 8 cents per share by a massive 237.5%.

      Tirthankar Chakraborty headshot

      New Strong Buy Stocks for May 1st

      Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Monday

        Baxter International (BAX) Beats on Earnings And Sales in Q1

        Baxter's adjusted earnings of 58 cents per share beat the Zacks Consensus Estimate of 51 cents and increased by 22 cents from the year-ago quarter.

          Will Baxter International (BAX) Disappoint in Q1 Earnings?

          Baxter International Inc. (BAX) is scheduled to report first-quarter 2017 earnings on Apr 26, before the opening bell.

            Why Is Baxter International (BAX) Up 5.5% Since the Last Earnings Report?

            Baxter International (BAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

              Baxter (BAX) Hits a 52-Week High: What's Driving the Stock?

              Share price of Baxter International Inc. (BAX), a global medical technology company, rallied to a new 52-week high of $51.43 on Mar 8, eventually closing a bit lower at $51.36.

                Baxter Partners ScinoPharm, Expands in Generic Injectables

                Baxter International Inc. (BAX) has formed a strategic partnership with Taiwan-based process R&D and active pharmaceutical ingredient (API) manufacturer, ScinoPharm Taiwan, Ltd.

                  Baxter International (BAX) Q4 Earnings Beat, Revenues Lag

                  Baxter International Inc. (BAX) reported fourth-quarter 2016 adjusted earnings of 57 cents per share, which surpassed the Zacks Consensus Estimate by 5 cents and were well above the year-ago figure of 43 cents.

                    Baxter International (BAX) Q4 Earnings Beat, Sales Miss

                    Baxter International's (BAX) adjusted earnings of 57 cents per share beat the Zacks Consensus Estimate of 52 cents and increased by 14 cents from the year-ago quarter.

                      Will Baxter International (BAX) Disappoint in Q4 Earnings?

                      Baxter International Inc. (BAX) is scheduled to report fourth-quarter 2016 earnings on Feb 1, before the opening bell.

                        Baxter (BAX): Sluggish Macro Environment Mars Prospects

                        On Jan 17, we issued an updated research report on Deerfield, IL-based Baxter International Inc. (BAX), a global medical technology company and leading provider of renal and hospital products.

                          Is Baxter Poised to Counter Low Cyclophosphamide Sales?

                          On Dec 30, we issued an updated research report on Deerfield, IL-based Baxter International Inc. (BAX), a global medical technology company and leading provider of renal and hospital products.

                            Boston Scientific Down on Risks; Innovations Raise Hope

                            On Dec 27 2016, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX).

                              Qiagen Poised on Fundamentals, Expansion Plans on Track

                              On Dec 23, 2016, we issued an updated research report on Netherlands-based molecular diagnostics provider Qiagen NV (QGEN).

                                Myriad Genetics: United Rheumatology Selects Vectra DA Test

                                Myriad Genetics, Inc.'s (MYGN) subsidiary, Crescendo Bioscience's Vectra DA assay has been added by United Rheumatology to its clinical practice guidelines for adults with rheumatoid arthritis.

                                  Henry Schein Named 2016's Best Animal Healthcare Provider

                                  Henry Schein, Inc. (HSIC) has been recognized as the "Best Animal Healthcare Product Provider 2016".

                                    VWR Plagued by Headwinds, Solid Fundamentals Raise Hope

                                    On Dec 20, we issued an updated research report on Radnor, PA-based VWR Corporation (VWR).

                                      Chemed (CHE): Roto-Rooter Solid, Reimbursement a Concern

                                      On Dec 20, we issued an updated research report on Cincinnati, OH-based Chemed Corporation (CHE).

                                        Walgreens Boots and Rite Aid to Vend 865 Stores to Fred's

                                        Walgreens Boots Alliance Inc. (WBA) has moved forward with regards to the impending acquisition of Rite Aid by recently announcing a $950 million deal to sell 865 Rite Aid stores.

                                          Amedisys' Unit to Buy Personal Care Provider, Home Staff

                                          Amedisys, Inc. (AMED) recently decided to buy a Massachusetts-based personal care provider, Home Staff, LLC.

                                            CVS Health (CVS) Down on Prevailing Risks, Tepid Guidance

                                            In Dec 19, 2016, we issued an updated research report on Rhode Island-based pharmacy retail giant CVS Health Corp. (CVS)

                                              Zimmer Biomet (ZBH): Spine Group Solid, Q3 Results a Drag

                                              On Dec 19, we issued an updated research report on Warsaw, IN-based Zimmer Biomet Holdings Inc. (ZBH).

                                                Align Technology Hits 52-Week High on Q3 & Dental Strength

                                                Share price of San Jose, CA-based Align Technology, Inc. (ALGN) scaled a new 52-week high of $102.1 on Dec 19, finally closing a bit lower at $100.3.

                                                  Bruker (BRKR) Buys Active Spectrum to Boost MRI Business

                                                  Bruker Corporation (BRKR) recently announced the acquisition of Active Spectrum Inc., a manufacturer of innovative benchtop micro-ESR spectroscopy systems.